magnifying glass
logo for Humira

Humira

Get Full Access

Who is Humira

In addition to its use in Crohn's disease, HUMIRA is also approved by the FDA for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. HUMIRA is indicated as a treatment to reduce signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients four years of age and older. HUMIRA is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage and improving physical function in patients with psoriatic arthritis. HUMIRA is also indicated for reducing signs and symptoms in patients with active ankylosing spondylitis. HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HUMIRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician. HUMIRA resembles antibodies normally found in the body. It works by blocking tumor necrosis factor alpha (TNF-alpha), an inflammatory protein that, when produced in excess, plays a key role in the inflammatory responses of some autoimmune diseases. To date, HUMIRA has been approved in 75 countries and more than 250,000 patients worldwide are currently being treated with HUMIRA. Clinical trials are currently under way evaluating the potential of HUMIRA in other immune-mediated diseases.Read More

Headquarters

Headquarters:

1 N Waukegan Rd, North Chicago, Illinois, 60064, United States
Phone Number

Phone Number:

(847) 932-7900
Employees

Employees:

55
Revenue

Revenue:

$10 Million
Humira's Social Media
SIC Code 28,283
NAICS Code 3254,32541
Popular Searches:

Humira

HUMIRA Complete

1.800.4HUMIRA

HUMIRA.com

AbbVie Inc

Top Competitors of Humira

Employess
54
revenue
$10 Million

2

Employess
32
revenue
$6 Million

3

Employess
130
revenue
$23 Million

4

Employess
<25
revenue
<$5 Million

8

Humira's Org Chart

PhonePhoneEmailEmail
Elise Wang
Elise Wang

Senior Knowledge Analyst

PhonePhoneEmailEmail

PhonePhoneEmailEmail

PhonePhoneEmailEmail
Illustration of an envelope

Humira Company Metrics

Company Insights
Employee Growth Rate
Revenue
QuarterRevenue

'21 - Q1

10388000

'21 - Q2

10388000

Humira's Tech Stack

Google Global Site Tag

By

Google

F5 BIG-IP Platform

By

F5

Brightcove

By

Brightcove

Fonts.com Web Fonts

By

Fonts
See more technologies

Humira News & Media

Alvotech Resolves U.S. Patent and Trade Secret Disputes with AbbVie, Securing U.S. Rights for Alvotech’s Proposed High-Concentration Biosimilar (AVT02) for Humira®

REYKJAVIK, Iceland--(BUSINESS WIRE)--Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, announced today that is has executed a U.S. settlement agreement with AbbVie (NYSE: ABBV) that grants Alvotech non-exclusive rights to market AVT02 (100mg/mL), its high-concentration, citrate-free biosimilar candidate for Humira® (adalimumab) in the United States. The settlement grants Alvot

Alvotech Announces Positive Top-Line Results for Switching Study Between Proposed Biosimilar AVT02 and Humira®

REYKJAVIK, Iceland--(BUSINESS WIRE)--Alvotech Announces Positive Top-line Results for Switching Study Between Proposed Biosimilar AVT02 and Humira®

HUMIRA (Adalimumab) Biosimilars Report 2021: Focus on Approved & Launched, Investigational & Research Use, Inactive/Terminated/Withdrawn, Industry/Non-Industry Partnerships - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "HUMIRA® (Adalimumab) Biosimilars: Focus on Approved & Launched Biosimilars, Investigational & Research Use Biosimilars, Inactive/Terminated/Withdrawn Biosimilars, Industry/Non-Industry Partnerships" report has been added to ResearchAndMarkets.com's offering. The "Adalimumab Biosimilars: Focus on Approved & Launched Biosimilars, Investigational & Research Use Biosimilars, Inactive/Terminated/Withdrawn Biosimilars, Industry/Non-Industry Partnerships"
Subscribe to "Humira" News

Frequently Asked Questions regarding Humira

Where are Humira’s headquarters?

Humira’s headquarters are in 1 N Waukegan Rd, North Chicago, Illinois, 60064, United States

What is Humira’s phone number?

Humira’s phone number is (847) 932-7900

What is Humira’s official website?

Humira’s official website is www.humira.com

What is Humira’s Revenue?

Humira’s revenue is $10 Million

What is Humira’s SIC code?

Humira’s SIC: 28,283

What is Humira’s NAICS code?

Humira’s NAICS: 3254,32541

How many employees are working in Humira?

Humira has 55 employees

What is Humira’s industry?

Humira is in the industry of: Drug Manufacturing & Research, Pharmaceuticals, Healthcare

Who are Humira’s main competitors?

Humira's main competitors are: National Rheumatoid Arthritis ..., DrugAbuse Sciences, Pet Health Network, Immunex

What is Humira's tech stack?

The technologies that are used by Humira are: Google Global Site Tag, F5 BIG-IP Platform, Brightcove, Fonts.com Web Fonts

See more information about Humira
4.4/5 on G2 Crowd